Drug
BI 1819479
BI 1819479: highest development phase Phase 1, developed by Boehringer Ingelheim. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| BI 1819479 NCT04801693 | Phase 1 | Healthy |
| BI 1819479 NCT05469646 | Phase 1 | Healthy |
Latest
No recent events.
Follow BI 1819479 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.